Documents
Application Sponsors
NDA 213556 | SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD | |
Marketing Status
None (Tentative Approval) | 001 |
Application Products
001 | TABLET;ORAL | 50MG; 300MG; 300MG | 0 | DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE |
FDA Submissions
TYPE 4; Type 4 - New Combination | ORIG | 1 | TA | 2020-10-06 | STANDARD |
Submissions Property Types
CDER Filings
SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 213556
[companyName] => SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD
[docInserts] => ["",""]
[products] => [{"drugName":"DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE","activeIngredients":"DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE","strength":"50MG; 300MG; 300MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"10\/06\/2020","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/213556Orig1s000TA_ltr.pdf\"}]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2020-10-06
)
)